Post-conditioning: Promising answers and more questions
© BioMed Central Ltd 2012
Published: 23 November 2012
Skip to main content
© BioMed Central Ltd 2012
Published: 23 November 2012
Volatile anesthetic agents have been used for decades in the peri-operative setting. Data from the past 15 years have shown that pre-injury administration of volatile anesthetic can decrease the impact of ischemia-reperfusion injury on the heart, brain, and kidney. Recent data demonstrated that volatile agents administered shortly after injury can decrease the ischemia-reperfusion injury. Several questions need to be answered to optimize this therapeutic target, but this is a promising era of secondary injury mitigation.
Cardiac anesthesia is associated with ischemia-reperfusion injury. Trying to limit the extent and mitigate the consequences of ischemia could potentially improve outcome after cardiac surgery. In the last 10 to 15 years, volatile agents have been shown to improve outcome in cardiac surgery. Despite these data, volatile anesthesia is not the most widely used technique for cardiac anesthesia. In the previous issue of Critical Care, Steurer and colleagues  presented interesting data on sevoflurane administration following cardiac surgery. These data have to be placed in the context of already-accumulated evidence and potential clinical applications.
Anesthetic gases are fascinating drugs: First-generation anesthetic gases, especially halothane, had significant cardiac side effects, increasing the risk of malignant arrhythmia and sensitizing the heart to catecholamines. Further generations, especially sevoflurane, have been shown to have interesting neuro- and cardioprotective properties. In the last 10 to 15 years, a wealth of data has shown that peri-operative administration of halogenated agents is associated with myocardial protection and better outcome.
Darwin proposed that species adapt to environment, the better-adapted breed having the better chances of survival. Interestingly, at the tissue, cell, mitochondrion, and possibly the gene level, there is a dynamic adaptation to the environment. This led to the concept of preconditioning, a mechanism in which brief sublethal periods of ischemia will provide protection from a subsequent lethal ischemia and mitigate the effect of ischemia-reperfusion . As stated by Friedrich Nietzsche, 'What does not destroy me, makes me stronger'. The organism or the tissue will acquire some 'injury-resistant' phenotype for a certain period of time . Ischemic pre-conditioning is an interesting and powerful concept, but its clinical applicability is limited by the already-jeopardized myocardium.
All hypnotics decrease myocardial consumption and may favor the myocardial oxygen supply/demand balance. On top of these macrohemodynamic effects, halogenated agents have intrinsic cardio- and neuroprotective effects that are similar to those of ischemic pre-conditioning. At a basic science level, the myocardial protection effects of sevoflurane involve apoptotic mRNA inhibition, neuromodulation, cytokine/inflammation modulation, redox-sensitive path ways, endothelial preservation, ion channels, notch signaling pathways, and probably other mechanisms to be discovered. This translates clinically as a decrease in post-cardiac surgery troponin levels, lower inotropes requirements, and better cardiac output. Preconditioning is well established, and volatile agents are now recommended as the agent of choice by the American Heart Association for high-risk patients .
Some research questions regarding sevoflurane post-conditioning
Is the post-conditioning effect related to the "dose" of sevoflurane? Is there a minimum duration or minimum alveolar concentration to obtain post-conditioning? Is there a dose response curve on sevoflurane post-conditioning?
Do all volatile anesthetic agents (isoflurane or desflurane) provide the same post-conditioning organ protection?
Does the lower release in cardiac damage markers shown by Steurer et al.  translate into outcome differences? Lower myocardial infarction rates? Lower inotropic support? Better cardiac output? Shorter intensive care unit/hospital stays? Lower mortality? Lower resource utilization?
How long is the therapeutic window after reperfusion to exhibit a post-conditioning organ protection? That is, how long after cardiopulmonary bypass or injury does sevoflurane have to be started to induce post-conditioning?
Is there an additional cardioprotective effect when sevoflurane is used intraoperatively (pre-conditioning)?
Is there a protective effect on other organs such as the brain or the kidney?
Animal data suggest that post-conditioning is better in males  and inhibited by hyperglycemia : Is post-conditioning beneficial only in males or in the context of tight glucose control (or both)?
Sevoflurane administration is associated with plasma fluoride levels above upper limit. How long can we use sevoflurane for sedation/post-conditioning in terms of fluoride toxicity?
Sevoflurane and isoflurane are very flexible generic anesthetic drugs administered daily by numerous anesthetists around the world. The demonstration of cardio-or neuroprotective effects (or both) when applied after the ischemia will make them interesting in myocardial ischemia, cardiogenic shock, or even traumatic brain injuries. Sevoflurane administration in the ICU has been done previously [12, 13]. It has been shown to be associated with fast awakening/weaning times after the drug is stopped . The anesthesia-conserving device has made the delivery simple and adaptable on 'regular' ICU-type ventilators. However, technical aspects such as gas analyzers, concentration measurement, and exhausted gas scavenging (most ICU-type ventilators release the exhaust gases into the environment) need to be taken into account. Educational aspects must include nurse training, dosage, availability of dantrolene, and training for the unlikely event of a malignant hyperthermia reaction. In addition, data show plasma fluoride concentration (39 ± 25 μmol/L) close to safety limits (50 μmol/L) at 24 and 48 hours after 9 hours of sevoflurane . Sevoflurane administration beyond 12 to 24 hours needs to be assessed in terms of fluoride plasma concentration and nephrotoxicity. Environmental effects of widespread anesthetic gas use need to be taken into account . Most cardiac surgery patients require a maximum of a few hours of mechanical ventilation (if any). In these circumstances, sevoflurane sedation in the cardiac ICU may be a very flexible option with an additional myocardial protection benefit.
Sevoflurane and possibly other volatile anesthetic agents show promising post-conditioning properties after cardiac surgery. This opens a new field of investigations and potential therapies aiming at mitigating secondary myocardial injury after the primary injury is done. More data are necessary to assess the magnitude conferred by this protection, its clinical relevance, the window of opportunity, and the collateral protection on other organs. Very promising answers, and more questions, are to come.
intensive care unit.